论文部分内容阅读
目的探讨缬沙坦联合氢氯噻嗪治疗高血压心脏病的临床疗效。方法选取高安市人民医院2014年1月—2015年1月收治的90例高血压心脏病患者,将患者随机分为对照组与干预组,各45例。对照组患者单纯接受缬沙坦治疗,干预组患者则接受缬沙坦联合氢氯噻嗪治疗,比较两组患者的临床疗效、不良反应发生率、治疗前后血压。结果干预组患者总有效率高于对照组,不良反应发生率低于对照组,差异有统计学意义(P<0.05)。治疗前两组患者血压比较,差异无统计学意义(P>0.05);治疗后干预组患者血压低于对照组,差异有统计学意义(P<0.05)。结论缬沙坦联合氢氯噻嗪治疗高血压心脏病的临床疗效较好,不良反应少。
Objective To investigate the clinical efficacy of valsartan combined with hydrochlorothiazide in the treatment of hypertensive heart disease. Methods 90 patients with hypertensive heart disease admitted from January 2014 to January 2015 in Gao’an Municipal People’s Hospital were selected and randomly divided into control group and intervention group, 45 cases in each group. Patients in the control group received valsartan alone. Patients in the intervention group received valsartan combined with hydrochlorothiazide. The clinical efficacy, incidence of adverse reactions, and blood pressure before and after treatment were compared between the two groups. Results The total effective rate of the intervention group was higher than that of the control group, the incidence of adverse reactions was lower than that of the control group, the difference was statistically significant (P <0.05). There was no significant difference in blood pressure between the two groups before treatment (P> 0.05). After treatment, the blood pressure of the intervention group was lower than that of the control group (P <0.05). Conclusion Valsartan combined with hydrochlorothiazide in the treatment of hypertensive heart disease has good clinical efficacy and few adverse reactions.